Provided by Tiger Trade Technology Pte. Ltd.

Candel Therapeutics, Inc.

5.17
+0.18003.61%
Volume:1.98M
Turnover:10.23M
Market Cap:378.67M
PE:-7.17
High:5.24
Open:5.01
Low:4.99
Close:4.99
52wk High:9.08
52wk Low:4.25
Shares:73.24M
Float Shares:45.48M
Volume Ratio:1.45
T/O Rate:4.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7210
EPS(LYR):-0.7210
ROE:-64.58%
ROA:-25.95%
PB:7.29
PE(LYR):-7.17

Loading ...

Candel Therapeutics Announces Positive Phase 3 Results for CAN-2409 in Prostate Cancer

Reuters
·
Nov 04, 2025

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

GlobeNewswire
·
Nov 03, 2025

Stephens Initiates Candel Therapeutics at Overweight With $15 Price Target

MT Newswires Live
·
Oct 28, 2025

Candel Therapeutics Initiated at Overweight by Stephens & Co.

Dow Jones
·
Oct 28, 2025

Candel Therapeutics initiated with an Overweight at Stephens

TIPRANKS
·
Oct 28, 2025

EXCLUSIVE: Trinity Capital's New Loan Fuels Bobbie's Mission To Set New US Infant Nutrition Standards

Benzinga_recent_news
·
Oct 23, 2025

Candel Therapeutics Initiated at Outperform by LifeSci Capital

Dow Jones
·
Oct 21, 2025

Candel Therapeutics initiated with an Outperform at LifeSci Capital

TIPRANKS
·
Oct 21, 2025

Candel Therapeutics appoints Pulendran to Candel’s RAB

TIPRANKS
·
Oct 16, 2025

Press Release: Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Dow Jones
·
Oct 16, 2025

Analysts Are Bullish on These Healthcare Stocks: Candel Therapeutics (CADL), Gain Therapeutics (GANX)

TIPRANKS
·
Oct 15, 2025

Candel Therapeutics Inc. Publishes Corporate Presentation Highlighting Positive Clinical Data for CAN-2409 and Pipeline Advances in Cancer Immunotherapy

Reuters
·
Oct 14, 2025

Candel Therapeutics announces interim data from phase 1b CAN-3110 trial

TIPRANKS
·
Oct 14, 2025

BRIEF-Candel Therapeutics Inc - Announces Encouraging Interim Data From CAN-3110 Trial

Reuters
·
Oct 14, 2025

Trinity Capital provides $130M in growth capital to Candel Therapeutics

TIPRANKS
·
Oct 14, 2025

Candel Therapeutics Secures $130 Million Term Loan Facility from Trinity Capital to Support Clinical and Commercial Initiatives

Reuters
·
Oct 14, 2025

Candel Therapeutics Enters Into $130 Million Term Loan Facility With Trinity Capital Inc.

THOMSON REUTERS
·
Oct 14, 2025

Candel Therapeutics Inc - Updated Median Os of 11.8 Months for Arm a, 12.0 Months for Arm B

THOMSON REUTERS
·
Oct 14, 2025

Candel Therapeutics Announces Positive Interim Phase 1b Data for CAN-3110 in Recurrent Glioblastoma

Reuters
·
Oct 14, 2025

Candel Therapeutics Announces Positive Phase 3 Results for CAN-2409 in Prostate Cancer and Presents New NSCLC Data at SITC 2025 Annual Meeting

Reuters
·
Oct 03, 2025